The University of Florence is an Italian public research university located in Florence, Italy. It comprises 12 schools and has about 60,000 students enrolled.

During the past decade, Università degli Studi di Firenze conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 2 clinical trials were completed, i.e. on average, 28.6% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Università degli Studi di Firenze" #1 sponsor was "University of Florence" with 2 trials, followed by "4SC AG" with 1 trials sponsored, "Astex Pharmaceuticals, Inc." with 1 trials sponsored, "Bausch & Lomb Incorporated" with 1 trials sponsored and "Celgene" with 1 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Università degli Studi di Firenze" #1 collaborator was "Catholic University of the Sacred Heart" with 1 trials as a collaborator, "Innovative Medicines Initiative" with 1 trials as a collaborator and "Italian Thyroid Cancer Observatory (ITCO) Foundation" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Università degli Studi di Firenze" are "Myelodysplastic Syndromes" (2 trials), "Rheumatoid Arthritis" (2 trials), "Acromegaly" (1 trials), "Adrenocortical Carcinoma" (1 trials) and "Alzheimer Disease" (1 trials). Many other conditions were trialed in "Università degli Studi di Firenze" in a lesser frequency.

Most popular intervention types in "Università degli Studi di Firenze" are "Drug" (12 trials), "Procedure" (4 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "ASTX727 LD" (1 trials), "ASTX727 SD" (1 trials), "Adalimumab" (1 trials) and "Azacitidine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Università degli Studi di Firenze" are 17 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Università degli Studi di Firenze". 1 are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Università degli Studi di Firenze, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Università degli Studi di Firenze, 2 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".

Università degli Studi di Firenze has several departments that took part in Clinical trials: "AOU Careggi; Neurologia 1-Dip. Neuroscienze Psicologia Area Farmaco Salute del Bambino(NEUROFARBA)" - 3 trials